DBV Technologies to Participate in Upcoming September Investor Conferences

DBV Technologies will present at three New York investor conferences in September 2026, with fireside chats webcast live and archived online.

Rhea-AI Summary

DBV Technologies (DBVT) will participate in three investor conferences in New York in September 2026, including the Cantor Global Healthcare Conference on September 9, Citi’s Biopharma Back to School Conference on September 10, and the H.C. Wainwright Global Investment Conference on September 15.

The company will host fireside chats at the Cantor and H.C. Wainwright events, at 1:00 p.m. ET and 3:00 p.m. ET respectively, with live webcasts available on its website for 90 days. DBV Technologies is a late-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) using its VIASKIN® Peanut Patch for toddlers and children with peanut allergy.

Market Context

A recent DBVT Form 4 recorded a sale of 464 shares by the chief medical officer, and insider activit...

Analysis

A recent DBVT Form 4 recorded a sale of 464 shares by the chief medical officer, and insider activity was classified as net selling. Against that context, the conferences provide scheduled access, but no new clinical or financial results.

Key Figures

Cantor conference date: September 9, 2026 Citi conference date: September 10, 2026 Wainwright conference date: September 15, 2026 +4 more

7 metrics

Cantor conference date September 9, 2026 2026 Cantor Global Healthcare Conference

Citi conference date September 10, 2026 2026 Biopharma Back to School Conference

Wainwright conference date September 15, 2026 H.C. Wainwright 28th Annual Global Investment Conference

Webcast availability 90 days Fireside-chat webcasts after the event

Toddler program age range 1 through 3 years Ongoing VIASKIN Peanut Patch clinical trials

Children's program age range 4 through 7 years Ongoing VIASKIN Peanut Patch clinical trials

ADS conversion 5 ordinary shares Each DBVT ADS

Historical Context

5 past events · Latest: Jul 30 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 30	ATM share sale	Negative	-2.2%	Approximately $50 million ADS sale implied dilution for existing shareholders
Jul 17	ATM prospectus filing	Neutral	-0.9%	Company refreshed its ATM program with up to $150 million of capacity
Jul 16	Half-year report filing	Neutral	-1.1%	Company filed its 2026 half-year report with the French market authority
Jul 16	2Q26 earnings report	Neutral	-1.1%	Regulatory progress and financial results were reported for the first half
Jul 14	Earnings date notice	Neutral	-1.3%	Company scheduled its second-quarter 2026 results and business update

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

All five selected historical events recorded negative 24-hour reactions, including the earnings and ATM announcements.

Key Terms

epicutaneous immunotherapy, epit, anaphylaxis

3 terms

epicutaneous immunotherapy medical

"Through epicutaneous immunotherapy (EPIT), the VIASKIN Peanut Patch is designed"

Epicutaneous immunotherapy is a treatment that delivers tiny, controlled doses of an allergen through a patch applied to the skin to retrain the immune system and reduce allergic reactions over time. Think of it as a slow, measured exposure training the body to tolerate a trigger rather than avoiding it entirely. Investors watch this approach because it represents a potentially safer, easier-to-administer alternative to injections or pills, with implications for market size, regulatory approval, and long-term treatment adoption in allergy therapeutics.

epit medical

"Through epicutaneous immunotherapy (EPIT), the VIASKIN Peanut Patch is designed"

Epit stands for epicutaneous immunotherapy, a medical approach that delivers tiny amounts of an allergen through a skin patch to teach the immune system to tolerate it over time. For investors, EPIT matters because it represents a non‑invasive, potentially lower‑cost and safer way to treat allergies that can broaden patient adoption, influence clinical development and approval timelines, and affect a product’s commercial reach—like gradually desensitizing someone with controlled, small exposures rather than a sudden large dose.

anaphylaxis medical

"symptoms varying in severity from mild to life-threatening anaphylaxis"

Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Châtillon, France, September 3, 2026

DBV Technologies to Participate in Upcoming September Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September:

2026 Cantor Global Healthcare Conference – September 9, 2026
Format:         Fireside Chat
Time:            1:00pm ET
Location:       New York, NY

Citi’s 2026 Biopharma Back to School Conference – September 10, 2026
Format:         1 on 1 Meetings
Location:       New York, NY

H.C. Wainwright 28^th Annual Global Investment Conference – September 15, 2026
Format:         Fireside Chat
Time:            3:00pm ET
Location:      New York, NY

Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com

Attachment

• PDF Version

FAQ

What investor conferences will DBV Technologies (DBVT) attend in September 2026?

DBV Technologies will attend three events in New York in September 2026: the Cantor Global Healthcare Conference on September 9, Citi’s Biopharma Back to School Conference on September 10, and the H.C. Wainwright Global Investment Conference on September 15.

When are DBV Technologies' fireside chats scheduled during the September 2026 conferences?

The company’s fireside chats are scheduled for 1:00 p.m. ET at the 2026 Cantor Global Healthcare Conference on September 9 and 3:00 p.m. ET at the H.C. Wainwright 28th Annual Global Investment Conference on September 15.

How can investors access the DBV Technologies (DBVT) webcasts for the September 2026 conferences?

Live webcasts of DBV Technologies’ fireside chats will be available in the Events section of the company’s website and will remain accessible for 90 days after each event.

Will DBV Technologies hold one-on-one meetings at the September 2026 conferences?

Yes. At Citi’s 2026 Biopharma Back to School Conference on September 10, DBV Technologies plans to participate in a format of one-on-one meetings with investors in New York.

What does DBV Technologies (DBVT) focus on in its biopharmaceutical programs?

DBV Technologies focuses on developing treatment options for food allergies and other immunologic conditions. It is currently investigating its proprietary VIASKIN® patch technology, including the VIASKIN Peanut Patch, as an epicutaneous immunotherapy (EPIT) approach.

What is the VIASKIN Peanut Patch being developed by DBV Technologies (DBVT)?

The VIASKIN Peanut Patch is designed to deliver microgram amounts of a biologically active compound through intact skin using epicutaneous immunotherapy (EPIT), aiming to desensitize individuals with peanut allergy by leveraging the skin’s immune tolerizing properties.

Which patient groups are included in DBV Technologies' ongoing VIASKIN Peanut Patch trials?

Ongoing clinical trials of the VIASKIN Peanut Patch include toddlers aged 1 to 3 years and children aged 4 to 7 years with peanut allergy.